Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline vs. Placebo for Symptom Reduction in Multiple Myeloma Maintenance
NCT01793051Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2013
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple myeloma (MM) comparing Minocycline with Placebo (2 arms). Primary endpoint: Symptom Reduction at 3 months. Started Mar 2013; status: completed.
02
Drugs
minocycline
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01793051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01793051.